MedTrace Logo

Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer

NCT00111839 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2018-04-06

Study results available
· View outcomes & findings →

Summary

This open-label, multicenter, randomized, controlled, Phase II study is planned to answer questions about how the drug, matuzumab (EMD 72000), works and is part of an effort aimed to develop better treatment for advanced lung cancer by combining matuzumab, a monoclonal antibody, with a chemotherapy treatment, called pemetrexed.

Conditions

Interventions

DRUG

Pemetrexed

Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.

DRUG

Matuzumab

Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.

Sponsors & Collaborators

Principal Investigators

  • Medical Responsible · EMD Serono Inc., an affiliate of Merck KGaA, Darmstadt, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-07-31
Completion
2009-03-31

Countries

  • United States
  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00111839 on ClinicalTrials.gov